Nanoviricides (NNVC) Other Non Operating Income (2010 - 2026)
Nanoviricides (NNVC) posted Other Non Operating Income of $40885.0 for Q1 2026, up 228.26% sequentially from $12455.0 in Q4 2025, and up 26.29% YoY from $32373.0 in Q1 2025.
Nanoviricides (NNVC) Other Non Operating Income (2010 - 2026) Analysis & Trends
Nanoviricides has reported Other Non Operating Income for 17 years, with the latest figure at $40885.0 in Q1 2026.
- Quarterly Other Non Operating Income rose 26.29% year-over-year to $40885.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $84689.0 (down 39.71% YoY) and the FY2025 annual result came in at $124828.0, down 54.07% from the prior year.
- Other Non Operating Income climbed to $40885.0 in Q1 2026 per NNVC's latest filing, from $12455.0 in the prior quarter.
- Over five years, Other Non Operating Income peaked at $107937.0 in Q1 2023 and troughed at $11627.0 in Q3 2025.
- A 5-year average of $54493.3 and a median of $41023.0 in 2024 frame the typical range for Other Non Operating Income.
- The sharpest annual moves came in 2022 and 2025: Other Non Operating Income surged 27858.51% in 2022, then plunged 71.66% in 2025.
- Over 5 years, Other Non Operating Income stood at $88954.0 in 2022, then fell by 6.54% to $83134.0 in 2023, then tumbled by 61.86% to $31709.0 in 2024, then plunged by 60.72% to $12455.0 in 2025, then surged by 228.26% to $40885.0 in 2026.
- According to Business Quant data, Other Non Operating Income over the past three periods registered $40885.0, $12455.0, and $11627.0 for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - |
| 10 | Nanoviricides | 28.74 Mn | 25.53 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 40,885.00 |
| Dec 31, 2025 | 12,455.00 |
| Sep 30, 2025 | 11,627.00 |
| Jun 30, 2025 | 19,722.00 |
| Mar 31, 2025 | 32,373.00 |
| Dec 31, 2024 | 31,709.00 |
| Sep 30, 2024 | 41,023.00 |
| Jun 30, 2024 | 35,374.00 |
| Mar 31, 2024 | 53,927.00 |
| Dec 31, 2023 | 83,134.00 |
| Sep 30, 2023 | 99,338.00 |
| Jun 30, 2023 | 106,380.00 |
| Mar 31, 2023 | 107,937.00 |
| Dec 31, 2022 | 88,954.00 |
| Sep 30, 2022 | 52,562.00 |
| Dec 31, 2021 | 2,073.00 |
| Sep 30, 2021 | 188.00 |
| Jun 30, 2021 | 3,081.00 |
| Mar 31, 2021 | 2,021.00 |
| Dec 31, 2020 | 1,187.00 |